AstraZeneca announces the sale of its West Chester site in Ohio, U.S., to National Resilience, a "technology-focused manufacturing company dedicated to broadening access to complex medicines." AstraZeneca expects to complete the sale in the first quarter of 2023, with a phased transition of services. Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca, said: "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio. The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients, as well as the continued employment for more than 500 people working at the West Chester site. I’m encouraged by Resilience’s plans to transform the site into their drug product centre of excellence."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca to acquire Neogene Therapeutics for $320M
- Merck, AstraZeneca announce EMA’s CHMP adopted positive opinion of LYNPARZA
- AstraZeneca Lynparza+biraterone recommended for E.U. approval in mCRPC
- AstraZeneca’s Imfinzi + chemotherapy recommended for approval in BTC
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for EU approval